Imutex Limited, formed in 2016, is a joint venture between SEEK Group and hVIVO plc to accelerate the development of a Broad-Spectrum Influenza Vaccine (BIV) and a Zika Vaccine.

The development of BIV and Zika vaccines are key public health priorities identified by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) in the United States.

Go to